Bagsværd, Denmark (ots/PRNewswire) - - The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy(TM) at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placebo - The trial also showed that 77.1% of study participants who received Wegovy(TM) lost at ...
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-weekly semaglutide 2.4 mg led to ...
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12-17 years.1 Over the last 20 years, the ...
Bagsværd, Denmark (ots/PRNewswire) - Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention. New results from the STEP phase 3a clinical trial programme demonstrated weight loss ...
Bagsværd, Denmark (ots/PRNewswire) - Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus IBT.[i] The STEP 3 phase 3a trial investigated ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only, excl US For journalistic assessment and preparation before publication. Today, Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analogue. In the ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only, excl US. For journalistic assessment and preparation before publication. - A separate real-world study showed that people with type 2 diabetes on two oral antidiabetic drugs who intensified with a glucagon-like peptide-1 ...
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda® (liraglutide 3.0 mg) in adolescents (aged ...
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk, a global healthcare company, and Noom, a leading behaviour change company, today announced a collaboration on digital health solutions focusing on weight management and education, with the aim of improving the lives of people living with obesity. The collaboration ...
Barcelona, Spain (ots/PRNewswire) - According to new data from the CONCLUDE head-to-head trial, Tresiba® (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in adults with type 2 diabetes ...
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk announced today the results from two Ozempic® (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed: - Ozempic® was superior to treatment with the SGLT-2 inhibitor canagliflozin (300 mg) in reducing HbA1c and ...
Barcelona, Spain (ots/PRNewswire) - Novo Nordisk today announced findings from an exploratory analysis of the PIONEER trial programme, showing oral semaglutide (3, 7 and 14 mg) improved glycaemic control in people with type 2 diabetes across baseline HbA1c levels. Greater reductions in HbA1c were demonstrated with 7 ...
Bagsværd, Denmark (ots/PRNewswire) - New data presented today at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed that, for people with advanced type 2 diabetes (>=10 years of diagnosis) not optimally controlled on their current basal-bolus regimen, Fiasp® (fast-acting ...
San Francisco (ots/PRNewswire) - Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The primary endpoint was defined as ...
Abstracts 54-OR and 55-OR Secondary data at 52 weeks demonstrated statistically significant blood sugar reductions and statistically significant reduction of body weight vs both Jardiance® and Victoza® San Francisco (ots/PRNewswire) - Findings presented today from two phase 3a clinical trials evaluated oral ...
New Orleans (ots/PRNewswire) - Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia® (sitagliptin 100 mg). Non-inferiority for oral semaglutide 3 mg for HbA1c reductions at 26 weeks was not confirmed. Presented today at the Endocrine Society Annual Meeting in ...
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology. The objective of this 30 week trial was to assess the efficacy and safety of Ozempic® (semaglutide) 1.0 mg when added to SGLT-2 inhibitor (SGLT-2i) ...
Berlin (ots/PRNewswire) - According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may achieve improved glycaemic control (HbA1c) with Tresiba® (insulin degludec) versus insulin glargine U100, without an increase in hypoglycaemia (potentially dangerous low blood ...
Berlin (ots/PRNewswire) - When treated with once-daily Ryzodeg®, people with type 2 diabetes achieved similar blood sugar control with half the number of daily injections, significantly lower total daily insulin dose and significantly reduced risk of nocturnal hypoglycaemia in the Step by Step trial compared with ...
Berlin (ots/PRNewswire) - New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and cultural factors.[1] Researchers linked factors such as food traditions and traditional gender roles to increasing vulnerability to diabetes in cities[1], where three-quarters ...
Bagsværd, Denmark (ots/PRNewswire) - - Cardiovascular disease (CVD) is the leading cause of disability and death in people with type 2 diabetes[1] - Despite the high incidence, 1 in 4 people with type 2 diabetes have never discussed, or cannot recall discussing, CVD risk factors with a doctor[2] - First-ever global ...
Athens, Greece (ots/PRNewswire) - Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of once-daily Norditropin® (somatropin) in a phase 2 trial in children with growth hormone deficiency.[1] There are currently no approved ...
Munich (ots/PRNewswire) - Ozempic® (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (collectively termed major adverse cardiovascular events, MACE) in people with type 2 diabetes at high ...
Orlando, Florida (ots/PRNewswire) - Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Findings from CONFIRM - a large real-world evidence (RWE) study comparing the ...
Orlando, Florida (ots/PRNewswire) - Poster Presentation #1083-P Ozempic® (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass index (BMI), with the greatest reductions occurring in adults ...
Orlando, Florida (ots/PRNewswire) - Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the PIONEER 1 phase 3a trial. The trial evaluated the efficacy and safety of ...
Bagsværd, Denmark (ots/PRNewswire) - Oral Presentation #127-OR Adults with type 2 diabetes treated with Xultophy® (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaemia and a lower insulin dose at 26 weeks Xultophy® (insulin degludec and liraglutide ...
Vienna (ots/PRNewswire) - People treated with Saxenda® (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European Congress on Obesity (ECO 2018) in Vienna, Austria and the 23rd Annual International Meeting of the ...
Glasgow, Scotland (ots/PRNewswire) - Adults with haemophilia B who received a single dose Refixia® (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed a longer half-life for ...
Glasgow, Scotland (ots/PRNewswire) - A new long term stability study has shown that haemophilia A treatment NovoEight® (turoctocog alfa) remains potent after three months exposure to temperatures of 40ºC.[1] The results were presented today at the WFH 2018 World Congress in Glasgow, UK. Treatment storage issues, ...